Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Fig. 1

Sequential infusion of anti-CD 19 and anti-CD22 CAR T cell therapy. a In vitro tumor-cytotoxicity effect of CART 19 and CART 22 cells at effector/target ratios of 25:1, 5:1 and 1:1. b Levels of IL-6 after CAR T cell therapy. c Levels of ferritin after CAR T cell therapy. d Dynamic white blood cell numbers and lymphocyte numbers before and after CAR T cell therapy. e Copies of lentivirus-containing CARs in the peripheral blood after CAR T cell therapy. f CAR T cell and B cell numbers after CAR T cell therapy. g The ratio of CD4+/CD8+ T cells in the peripheral blood after CAR T cell therapy

Back to article page